A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Completed · Phase 2 · NCT05227703

Conditions: Schizophrenia

Research payments reported, 2025: $3.4M
U.S. investigators named: 16
Sites paid: 15
Planned or actual enrollment: 391

About the trial

Sponsor: AbbVie
Tested: Emraclidine 15 mg (drug), Emraclidine 30 mg (drug), Placebo (drug)
Dates: Started 2022-07-05; completion 2024-09-11
Results posted: Yes

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female adult participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.

From ClinicalTrials.gov, last updated 2025-10-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $3.4M in research payments for this study in 2025 (83 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it